CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Mifepristone and misoprostol

Last Updated: April 20, 2017
Result type: Reports
Project Number: SR0502-000
Product Line: Reimbursement Review

Generic Name: Mifepristone and misoprostol

Brand Name: Mifegymiso

Manufacturer: Celopharma Inc.

Therapeutic Area: Medical termination of pregnancy (gestational age up to 49 days)

Indications: Medical termination of pregnancy

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 18, 2017

Recommendation Type: Reimburse